amsacrine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
acridine derivatives	203	51264-14-3

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

amsacrine
acridinylanisidide
amekrin
amsidil
amsidine
amsidyl
lamasine

An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.

Molecular weight: 393.46
Formula: C21H19N3O3S
CLOGP: 4.54
LIPINSKI: 0
HAC: 6
HDO: 2
TPSA: 80.32
ALOGS: -5.09
ROTB: 4

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	10 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	10.05 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	1.60 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	4.30 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.03 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	4.70 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1987	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute myeloid leukaemia recurrent	84.86	74.40	14	463	1609	63486936
Graft versus host disease	82.17	74.40	17	460	6746	63481799

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute myeloid leukaemia recurrent	122.69	113.25	21	351	2149	34954410

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute myeloid leukaemia recurrent	161.54	73.84	28	745	3355	79740260
Venoocclusive liver disease	126.70	73.84	28	745	11743	79731872
Drug resistance	95.51	73.84	29	744	42184	79701431
Graft versus host disease	73.93	73.84	19	754	15007	79728608

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01XX01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Other antineoplastic agents
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:50750	inhibitors of type II topoisomerase
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D007202	Indicators and Reagents
MeSH PA	D007364	Intercalating Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.98	acidic
pKa2	8.25	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	6.68		CHEMBL
Cytochrome P450 2D6	Enzyme	P10635	CP2D6_HUMAN		Ki	5.12		WOMBAT-PK
DNA topoisomerase 2-alpha	Enzyme	P11388	TOP2A_HUMAN		IC50	5		CHEMBL
DNA topoisomerase I, mitochondrial	Enzyme	Q969P6	TOP1M_HUMAN		IC50	7.43		WOMBAT-PK
DNA topoisomerase 1	Enzyme	P11387	TOP1_HUMAN		IC50	7.43		WOMBAT-PK
DNA topoisomerase 2-beta	Enzyme	Q02880	TOP2B_HUMAN		EC50	4.96		CHEMBL
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	5.30		CHEMBL
DNA topoisomerase II	Enzyme	P11388 Q02880	TOP2A_HUMAN TOP2B_HUMAN		EC50	6.14		CHEMBL

External reference:

ID	Source
4025233	VUID
N0000171765	NUI
D02321	KEGG_DRUG
151347	RXNORM
C0002699	UMLSCUI
CHEBI:2687	CHEBI
ASW	PDB_CHEM_ID
CHEMBL43	ChEMBL_ID
D000677	MESH_DESCRIPTOR_UI
DB00276	DRUGBANK_ID
2179	PUBCHEM_CID
4864	INN_ID
00DPD30SOY	UNII
326955000	SNOMEDCT_US
391774005	SNOMEDCT_US
4025233	VANDF
003469	NDDF

Pharmaceutical products:

None